Skip to main content
. 2021 Feb 10;15:628403. doi: 10.3389/fnins.2021.628403

FIGURE 3.

FIGURE 3

High-dose candesartan treatment did not alter hippocampal angiotensin peptide and receptor levels compared to vehicle treatment in female and male E4FAD− and E4FAD+ mice. In female and male E4FAD− and E4FAD+ mice treated with 10 mg/kg/day candesartan (high dose), there were no differences in hippocampal levels of (A) angiotensin II when assessed by ELISA analysis [Female E4FAD−: t(18) = 0.15, p = 0.88. Female E4FAD+: t(17) = 1.85, p > 0.081. Male E4FAD−: t(8) = 2.23, p = 0.056. Male E4FAD+: t(8) = 1.53, p = 0.16] as well as (B) angiotensinogen, AT1 receptor, or AT2 receptor levels compared to vehicle when assessed by western blot analysis [Angiotensinogen: Female E4FAD−: t(17) = 1.30, p = 0.21. Female E4FAD+: t(22) = 0.81, p = 0.43. Male E4FAD−: t(10) = 0.27, p = 0.79. Male E4FAD+: t(9) = 1.19, p = 0.26. AT1: Female E4FAD−: t(18) = 1.00, p = 0.33. Female E4FAD+: t(21) = 0.09, p = 0.92. Male E4FAD−: t(10) = 2.28, p = 0.073. Male E4FAD+: t(9) = 1.44, p = 0.18. AT2: Female E4FAD−: t(18) = 1.00, p = 0.33. Female E4FAD+: t(22) = 0.21, p = 0.84. Male E4FAD−: t(10) = 1.04, p = 0.32. Male E4FAD+: t(9) = 1.45, p = 0.17]. In (B) quantification of each protein was normalized to GAPDH as a loading control and all data are expressed as a ratio to vehicle-treated mice. All data expressed as mean +/− SEM. p > 0.05 by Student’s t-test. See Supplementary Table 2 for details on n sizes.